-
Mashup Score: 0NOVA Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer - The ASCO Post - 11 month(s) ago
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators reported at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.1 Once…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma - The ASCO Post - 11 month(s) ago
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Joyce F. Liu, MD, MPH, Associate Chief and Director of Clinical…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma https://t.co/TqWnbldci1 #gyncsm #uterinecancer #oncology #SGO23 #SGOmtg @SGO_org
-
-
Mashup Score: 5GOG 3026 Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer - The ASCO Post - 11 month(s) ago
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD, Professor of Obstetrics and Gynecology at Florida International University and Director of Gynecologic…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCOPost: GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer https://t.co/YTLwAiiWer #gyncsm…
-
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer https://t.co/YTLwAiiWer #gyncsm #ovariancancer #oncology #SGO23 #SGOmtg @SGO_org
-
-
Mashup Score: 0Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer - The ASCO Post - 12 month(s) ago
Treatment with the folate receptor alpha (FRα)-targeted antibody-drug conjugate mirvetuximab soravtansine-gynx benefited patients with FRα-high, platinum-resistant ovarian cancer, even after multiple lines of prior therapy, according to an updated analysis of the SORAYA trial presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.1 Predictably, the highest…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Final SORAYA Analysis Supports Mirvetuximab Soravtansine in Ovarian Cancer https://t.co/ojMzKIs4Dd #gyncsm #ovariancancer #oncology #SGO23
-
-
Mashup Score: 0Mansoor R Mirza on Endometrial Cancer New Findings on Dostarlimab gxly Plus Chemotherapy - The ASCO Post - 12 month(s) ago
SGO 2023 Annual Meeting on Women’s Cancer Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlimab-gxly plus carboplatin and paclitaxel increased progression-free survival in patients with primary advanced or recurrent endometrial…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy https://t.co/DdN2merFDl #gyncsm #endometrialcancer #oncology #SGO23 #SGO_mtg @SGO_org @MirzaCPH @Rigshospitalet
-
-
Mashup Score: 0Ursula A Matulonis on Ovarian Cancer New Data on Niraparib From the ENGOT OV16 NOVA Trial - The ASCO Post - 12 month(s) ago
Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile in patients with mutated, advanced-stage ovarian…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial https://t.co/HMEzatNEav #SGO23 #SGOmtg #gyncsm #ovariancancer @SGO_org @DanaFarber
-
-
Mashup Score: 0GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer - The ASCO Post - 1 year(s) ago
By Caroline Helwick Posted: 4/27/2023 1:28:00 PM Last Updated: 4/27/2023 1:50:44 PM The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer https://t.co/PwsLEQoIaM #SGOmtg #SGO23 #gyncsm #EndometrialCancer #oncology #radonc
-
-
Mashup Score: 0Meghan Berkenstock on Managing Ocular Toxicities With ADCs in Cervical and Ovarian Cancers - 1 year(s) ago
Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams. #gyncsm #ovariancancer #cervicalcancer #SGO23 Watch the full interview: https://t.co/Cit7mK5ofz https://t.co/U0VLp7yiIW
-
-
Mashup Score: 2Shannon N Westin on Ovarian Cancer Results From the NOW Trial of Neoadjuvant Olaparib in BRCA PALB or RAD51C Mutant Disease - The ASCO Post - 1 year(s) ago
SGO 2023 Annual Meeting on Women’s Cancer Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile in patients with mutated, advanced-stage ovarian cancer. Even in patients with stage IV disease, surgical outcomes were favorable after…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease https://t.co/DCyeYBy47J #gyncsm #ovariancancer #genetics #oncology #SGO23 #SGO_mtg @SGO_org @ShannonWestin @MDAndersonNews
-
-
Mashup Score: 1Shannon N Westin on Endometrial and Ovarian Cancers New Data on Selumetinib and Olaparib From the SOLAR Trial - The ASCO Post - 1 year(s) ago
Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile in patients with mutated, advanced-stage ovarian…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Shannon N. Westin, MD, MPH, on Endometrial and Ovarian Cancers: New Data on Selumetinib and Olaparib From the SOLAR Trial https://t.co/WN3OBXwMQq #gyncsm #endometrialcancer #ovariancancer #SGO23 #SGO_mtg @SGO_org @ShannonWestin @MDAndersonNews
-
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer https://t.co/uKZSvuwi2K #SGO23 #SGOmtg @SGO_org #gyncsm #ovariancancer #oncology